Inventiva (NASDAQ:IVA) Coverage Initiated by Analysts at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of Inventiva (NASDAQ:IVA) in a report released on Friday, MarketBeat reports. The brokerage issued an overweight rating on the stock.

IVA has been the subject of several other research reports. Wall Street Zen downgraded shares of Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a report on Tuesday, April 21st. Finally, Truist Financial began coverage on shares of Inventiva in a research note on Thursday, March 19th. They issued a “buy” rating and a $13.00 price objective on the stock. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $16.56.

Inventiva Trading Up 2.2%

Shares of NASDAQ IVA opened at $4.62 on Friday. The company has a 50 day simple moving average of $4.36 and a 200 day simple moving average of $5.32. Inventiva has a 1 year low of $2.85 and a 1 year high of $7.98.

Institutional Trading of Inventiva

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IVA. Paradigm Biocapital Advisors LP bought a new position in Inventiva during the 4th quarter worth approximately $18,600,000. ADAR1 Capital Management LLC bought a new stake in shares of Inventiva in the 4th quarter valued at $12,601,000. Millennium Management LLC boosted its stake in shares of Inventiva by 2,267.7% in the 4th quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock valued at $12,334,000 after purchasing an additional 2,540,540 shares during the last quarter. UBS Group AG increased its position in shares of Inventiva by 28,881.6% during the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after buying an additional 2,634,580 shares during the period. Finally, SymBiosis Capital Partners LLC acquired a new stake in shares of Inventiva during the fourth quarter worth $12,090,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.